Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AIMT

Aimmune Therapeutics (AIMT) Stock Price, News & Analysis

Aimmune Therapeutics logo

About Aimmune Therapeutics Stock (NASDAQ:AIMT)

Advanced Chart

Key Stats

Today's Range
$34.49
$34.49
50-Day Range
$34.30
$34.59
52-Week Range
$10.09
$37.00
Volume
N/A
Average Volume
1.71 million shs
Market Capitalization
$2.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AIMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AIMT Stock News Headlines

Aimtron Electronics Ltd (AIMT)
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
Aimmune Closes Enrolment in Phase III Peanut Allergy Study
See More Headlines

AIMT Stock Analysis - Frequently Asked Questions

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) announced its quarterly earnings results on Thursday, July, 30th. The biotechnology company reported ($1.06) EPS for the quarter, meeting analysts' consensus estimates of ($1.06).

Aimmune Therapeutics (AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Meta Platforms (META), Xtrackers California Municipal Bond ETF (CA) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
7/30/2020
Today
8/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AIMT
CIK
1631650
Fax
N/A
Employees
228
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$248.50 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-164.99%
Return on Assets
-89.50%

Debt

Debt-to-Equity Ratio
0.73
Current Ratio
7.53
Quick Ratio
7.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.66 per share
Price / Book
20.78

Miscellaneous

Outstanding Shares
65,450,000
Free Float
N/A
Market Cap
$2.26 billion
Optionable
Optionable
Beta
1.76
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:AIMT) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners